Printer Friendly

Success or Failure of Antidepressant Citalopram Predicted by Gene Variation - August 1, 2007.

A variation in a gene called GRIK4 appears to make people with depression more likely to respond to the medication citalopram (Celexa) than are people without the variation, a study by the National Institute of Mental Health (NIMH), part of the National Institutes of Health, has found. The increased likelihood was small, but when people had both this variation and one in a different gene shown to have a similarly small effect in an earlier study, they were 23 percent more likely to respond to citalopram than were people with neither variation.

To read the full text of this article, click here:
COPYRIGHT 2007 National Institutes of Health
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:National Institutes of Health: News and Events
Date:Aug 2, 2007
Previous Article:Progesterone Treatment Does Not Prevent Preterm Birth in Twin Pregnancy - August 1, 2007.
Next Article:New Grants Bolster Efforts to Generate Faster and Cheaper Tools for DNA Sequencing - August 1, 2007.

Related Articles
Mood meds' second wind: depression drugs aided by extra treatment step.
About 25% remit with second-try antidepressant.
Allele could pinpoint responders to SSRIs.
Dangerous DNA: genes linked to suicidal thoughts with med use.
Genetic tests, FDA, and warfarin.
Pharmacogenetics inform drug choice, dosage.

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |